Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 7/20 | 0.46 |
| ▸ | NPY4R | P50391 | 7/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.46 |
| ▸ | NPY1R | P25929 | 5/20 | 0.46 |
| ▸ | RAMP3 | O60896 | 7/20 | 0.46 |
| ▸ | CALCR | P30988 | 7/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.45 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.45 |
| ▸ | GLP1R | P43220 | 2/20 | 0.45 |
| ▸ | GIPR | P48546 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22019191 | 1.00 | NPY2R (0.46) | NPY2RNPY4RNPY5RNPY1RRAMP3 | |
| SCHEMBL22018329 | 0.96 | NPY2R (0.47) | NPY2RNPY4RNPY5RNPY1RGLP1R | |
| SCHEMBL22018604 | 0.96 | APLNR (0.45) | NPY2RNPY4RNPY5RNPY1RRAMP3 | |
| SCHEMBL25524960 | 0.96 | RAMP3 (0.46) | NPY2RNPY4RNPY5RNPY1RRAMP3 | |
| SCHEMBL22018477 | 0.96 | APLNR (0.46) | NPY2RNPY4RNPY5RNPY1RRAMP3 | |
| SCHEMBL22922932 | 0.96 | APLNR (0.46) | NPY2RNPY4RNPY5RNPY1RRAMP3 | |
| SCHEMBL22018361 | 0.96 | APLNR (0.46) | NPY2RNPY4RNPY5RNPY1RRAMP3 | |
| SCHEMBL22019133 | 0.96 | RAMP3 (0.44) | NPY2RNPY4RNPY5RNPY1RRAMP3 | |
| SCHEMBL22018328 | 0.95 | NPY2R (0.47) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL29308339 | 0.95 | NPY2R (0.45) | NPY2RNPY4RNPY5RNPY1RGLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210024577-A1 | NOVEL PEPTIDE AND PHARMACEUTICAL COMPOSITION FOR TREATING AN EYE DISEASE COMPRISING THE SAME AS AN ACTIVE PHARMACEUTICAL INGREDIENT | YUYU PHARMA, INC. (KR) | 2021-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024577-A1 | NOVEL PEPTIDE AND PHARMACEUTICAL COMPOSITION FOR TREATING AN EYE DISEASE COMPRISING THE SAME AS AN ACTIVE PHARMACEUTICAL INGREDIENT | VIP, NGLY1, PROKR1 | NPY2R 727/4885NPY4R 1291/4885NPY5R 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.